Merck & Co. logo
Merck & Co. MRK
$ 121.57 -1.82%

Annual report 2025
added 02-24-2026

report update icon

Merck & Co. Gross Profit 2011-2026 | MRK

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Merck & Co.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - 32.7 B 28.8 B 27.3 B 25.9 B 24.6 B 25.5 B 27.1 B 30.8 B 31.2 B

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
32.7 B 24.6 B 28.2 B

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
11.1 M $ 6.03 -1.55 % $ 885 M usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
97.3 M $ 19.2 -11.52 % $ 554 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
9.67 M $ 10.89 -30.36 % $ 530 M niderlandNiderland
GT Biopharma GT Biopharma
GTBP
27 K $ 0.47 -2.41 % $ 892 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
-18.3 M $ 3.36 0.86 % $ 1.2 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
117 M $ 29.16 -3.54 % $ 1.69 B usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
325 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
160 M - - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
156 K $ 1.38 -0.72 % $ 63.3 M israelIsrael
Altimmune Altimmune
ALT
8.18 K $ 4.21 -2.32 % $ 299 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
45.3 M - -13.85 % $ 16.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
5.83 M $ 0.84 -4.24 % $ 27.9 M israelIsrael
Viela Bio, Inc. Viela Bio, Inc.
VIE
9.61 M - - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
121 M $ 13.98 1.27 % $ 5.7 B irlandaIrlanda
AbbVie AbbVie
ABBV
12.1 B $ 233.57 0.64 % $ 413 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
-643 K $ 0.8 -11.6 % $ 38.5 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 0.83 5.37 % $ 4.53 M chinaChina